HIV Vaccines
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of the section “HIV Vaccines” is to describe current experimental and conceptual advances in the development of HIV vaccines.
Scope
We will consider manuscripts investigating anti-HIV immunity, immunological responses to potential HIV vaccine antigens, the testing of HIV vaccine candidates in animals and humans, delivery methods of HIV vaccine antigens, studies of vaccine adjuvants related to HIV vaccine development, investigations of HIV vaccine strategies aimed to raise broadly neutralizing antibodies, and theoretical studies suggesting and rationalizing new types of HIV vaccine or new ways of stimulating protective anti-HIV immunity. The section will publish different types of manuscripts, including short definitive reports, full-size papers, and reviews. All submissions will undergo rigorous peer review.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Neutralizing Antibodies and Vaccine Development against the HIV-1 Virus (Deadline: 30 May 2024)
- HIV Vaccine Development and Clinical Trails (Deadline: 30 June 2024)
- Advances in HIV Vaccine Development (Deadline: 31 July 2024)